Previous 10 | Next 10 |
home / stock / aavxf / aavxf news
As Chief People Officer of Abivax, Ida Hatoum will be leading the organizational strategy to build and strengthen the Abivax team in the United States and Europe across all functions Ida has a proven track record in talent acquisition and development in the biopharmaceutical industry PAR...
PARIS, FRANCE / ACCESSWIRE / May 15, 2023 / Abivax (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, informs its shareholders that its ordi...
PARIS, FRANCE / ACCESSWIRE / May 4, 2023 / Abivax (Euronext Paris: FR0012333284 - ABVX) (the "Company"), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces today the pub...
The authors of the expert article published in the Journal of Crohn's and Colitis include major European and North American Key Opinion Leaders in the field of Inflammatory Bowel Diseases The KOLs state that obefazimod is a first-in-class drug with a unique mechanism of action and with great...
2023-04-22 16:00:00 ET Treatments for ulcerative colitis (UC) are projected to reach $9.6B in eight major markets by 2031 driven by an increase in the patient population and new therapies coming to market. That's the assessment from data and analytics firm GlobalData, which sees a 2...
Obefazimod global pivotal phase 3 program (ABTECT program) in moderate to severe ulcerative colitis (UC) early enrollment progressing according to plan Abivax reports promising Phase 2b maintenance results with 52.5% of UC patients in clinical remission after two years of continued oral dail...
Michael Ferguson has a strong track record in the biopharmaceutical industry, having held senior positions for commercialization and marketing of drugs in the field of Gastroenterology and specifically in Inflammatory Bowel Diseases (IBD) As CCO of Abivax, Michael Ferguson will be leading th...
The analysis demonstrates clinical remission in 52.5% (n=114) of 217 moderate to severe ulcerative colitis (UC) patients (intent-to-treat population, ITT) after two years (96 weeks) of once-daily oral 50mg obefazimod In the subgroup of patients who did not achieve a clinical remission after ...
Marc's appointment bolsters Abivax's position as a leader in the field of chronic inflammatory bowel diseases Corinna zur Bonsen-Thomas steps down as acting Chair and remains a Board Member Prof. Hartmut J. Ehrlich, M.D., retires from the CEO position PARIS, FRANCE / ACCESSWIRE / A...
PARIS, FRANCE / ACCESSWIRE / March 16, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces an update of its 2...
News, Short Squeeze, Breakout and More Instantly...
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025 Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with ...
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabi...
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients...